Nishiyama M, Noso Y, Yamaguchi M, Hirabayashi N, Toge T, Niimoto M, Hattori T
Gan To Kagaku Ryoho. 1986 Feb;13(2):275-9.
Subrenal capsule assay(SRC assay) has been reported to be an effective and rapid method for predicting the tumor sensitivity of individual patients to anti-cancer agents. In order to establish a more objective method of determining sensitivity in SRC assay the DNA content was measured by the schmidt-Thannhauser-Schneider method and the protein content was estimated using Bio-Rad protein assay, after removal of a tumor implanted in the subrenal capsular space of ddY mice. Percentage inhibition of DNA/protein had a high correlation with that of relative increase of tumor weight, although three groups treated with mitomycin-C, 5-fluorouracil and cyclophosphamide indicated different values of tumor sensitivity. From these results, the percentage inhibition of DNA/protein seems to be more objective than microscopic measurement for predicting tumor sensitivity.
肾包膜下测定法（SRC测定法）据报道是一种预测个体患者对抗癌药物肿瘤敏感性的有效且快速的方法。为了在SRC测定法中建立一种更客观的确定敏感性的方法，在去除植入ddY小鼠肾包膜下间隙的肿瘤后，采用施密特 - 坦豪泽 - 施耐德方法测量DNA含量，并使用伯乐蛋白质测定法估算蛋白质含量。DNA/蛋白质抑制百分比与肿瘤重量相对增加的百分比具有高度相关性，尽管用丝裂霉素C、5-氟尿嘧啶和环磷酰胺治疗的三组显示出不同的肿瘤敏感性值。从这些结果来看，DNA/蛋白质抑制百分比在预测肿瘤敏感性方面似乎比显微镜测量更客观。
